Navigation Links
Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
Date:2/12/2008

bavituximab in combination with chemotherapy. The first bavituximab breast cancer trial is now underway and the two other trials are expected to begin soon. Bavituximab is in clinical trials in the U.S. in patients with advanced solid tumors and in patients co-infected with HCV and HIV.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and hepatitis C virus (HCV) infection. The company is pursuing three separate clinical programs in cancer and HCV infection with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (http://www.avidbio.com), which provides development and bio-manufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at http://www.peregrineinc.com.

Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to, the risk that the company will experience delays or difficulties in enrolling patients in the study, the risk that the standard docetaxel response rate will not be improved as a result of the combination therapy, and the risk that the results from this trial will not be consistent with the results of prior trials or preclinical studies. It is important to note that the company's actual results could differ materially from th
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
2. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
3. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
4. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
5. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
6. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
7. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
8. Access Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
9. XTL Biopharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
10. Koronis Pharmaceuticals Appoints David Drajeske Director of Business Development
11. Onyx Pharmaceuticals to Present at BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... 24, 2014 ... has announced the addition of the  "The ... Other 2-D Nanomaterials "  report to their ... ,CNTs and graphene are the strongest, lightest ... with a performance-per-weight greater than any other ...
(Date:10/22/2014)... The North American crystal oscillator market report ... analysis and forecast of revenue. This market was valued ... reach $623.6 million by 2018, at a CAGR of ... TOC of the North American crystal oscillator market report, ... This also provides a glimpse of the segmentation of ...
(Date:10/22/2014)... 2014 Grace Century, a private equity ... announces the addition of Dr. Yousef “Josh” Siddiqui ... team. Dr. Siddiqui will provide further healthcare expertise to ... of University College Medical School in the ... in 2001. With further certification as a General Practitioner ...
(Date:10/22/2014)... Nuvilex, Inc. (OTCQB: NVLX) – According to ... are living with diabetes, with  that number expected to ... market for diabetes treatments is approximately $500 billion.  ... from pancreatic cancer.  Pancreatic cancer is the fourth most ... the United States , and according to ...
Breaking Biology Technology:The Global Market for Carbon Nanotubes, Graphene and Other 2-D Nanomaterials 2The Global Market for Carbon Nanotubes, Graphene and Other 2-D Nanomaterials 3The Global Market for Carbon Nanotubes, Graphene and Other 2-D Nanomaterials 4The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 2The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 3The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 4Dr. Yousef Siddiqui joins the Grace Century Advisory Team 2Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2
... Phosphatase useful for dephosphorylation serine,threonine or tyrosine ... Mary Ellen Simcox ,Stratagene Cloning Systems, Inc. ... dualspecificity protein,phosphatase that has been produced as ... calmodulinbinding peptide. The tag simplifies purification of ...
... polymerase delivers high fidelity and great,performance ... Holly Hogrefe ,Stratagene , Stratagene has ... novel enzyme formulation that provides,superior performance in ... that Herculase enhanced DNA polymerase is even ...
... Generate cDNA libraries with as little as 50 ng ... Tanya Hosfield ,Marie Callahan ,John C. Bauer Mike ... Lenhart Paul Young ,Human Genome Sciences, Rockville, Maryland , ... new method to generate high-efficiency cDNA libraries in a plasmid,vector. ...
Cached Biology Technology:Highly Active and Removable AffinityTagged Lambda Phosphatase 2Highly Active and Removable AffinityTagged Lambda Phosphatase 3Highly Active and Removable AffinityTagged Lambda Phosphatase 4Unique DNA Polymerase Formulation Excels in a Broad Range of PCR,Applications 2Unique DNA Polymerase Formulation Excels in a Broad Range of PCR,Applications 3Unique DNA Polymerase Formulation Excels in a Broad Range of PCR,Applications 4Unique DNA Polymerase Formulation Excels in a Broad Range of PCR,Applications 5Unique DNA Polymerase Formulation Excels in a Broad Range of PCR,Applications 6Unique DNA Polymerase Formulation Excels in a Broad Range of PCR,Applications 7Unique DNA Polymerase Formulation Excels in a Broad Range of PCR,Applications 8Unique DNA Polymerase Formulation Excels in a Broad Range of PCR,Applications 9Unique DNA Polymerase Formulation Excels in a Broad Range of PCR,Applications 10Constructing Directional cDNA Libraries from Limited Amounts of RNA 2Constructing Directional cDNA Libraries from Limited Amounts of RNA 3Constructing Directional cDNA Libraries from Limited Amounts of RNA 4Constructing Directional cDNA Libraries from Limited Amounts of RNA 5Constructing Directional cDNA Libraries from Limited Amounts of RNA 6Constructing Directional cDNA Libraries from Limited Amounts of RNA 7
(Date:10/18/2014)... 2,000 patients referred for evaluation of suspected genetic ... for 25 percent, including detection of a number ... to disease, according to a study appearing in ... to coincide with the American Society of Human ... exons or coding regions of thousands of genes ...
(Date:10/17/2014)... knowledge regarding Ebola is critical and pertinent for practicing ... global outbreak and epidemic. The Journal, Disaster Medicine ... issue, Ebola Virus and Public Health, to surround the ... this critical societal moment. , On October 17, ... Clinicians . The primer was prepared by Dr. Eric ...
(Date:10/17/2014)... of Copenhagen have shown for the first time how ... fibrosis patients, giving them the opportunity to get tremendous ... , The study also discovered the bacterial growth in ... halted or slowed down by the immune cells. The ... and helped "suffocate" the bacteria, forcing the bacteria to ...
Breaking Biology News(10 mins):Whole-exome sequencing shows potential as diagnostic tool 2Scientists opens black box on bacterial growth in cystic fibrosis lung infection 2
... MADISON, WI, MARCH 1, 2011 Methane ... permafrost, termites, oceans, freshwater bodies, non-wetland soils, are all ... methane presence ca n be accredited to human-related activities. ... burning, waste management and animal husbandry. The release of ...
... available in Spanish . , Those who ... and teas may tend to overlook the benefits of drinking ... Agricultural Research magazine, the idea that herbal teas may provide ... U.S. Department of Agriculture (USDA)-funded scientists in Boston, Mass., ...
... release is available in Spanish . ... (UPV/EHU), has developed genetic-molecular tools, with the intention of completing ... equine breeds in the Basque Country Autonomous Community (CAPVEAE) and ... DNA sequence) and certain SNPs (a kind of variation in ...
Cached Biology News:Measuring methane 2Don't underestimate the power of herbal teas 2Basque thesis investigates wide diversity within certain ovine, bovine and equine breeds 2Basque thesis investigates wide diversity within certain ovine, bovine and equine breeds 3
... I can be used in intracellular staining ... cells and to serve as an antibody ... cell permeabilization is a reversible process, it ... the presence of saponin during intracellular staining. ...
... raised against a partial recombinant ... PPP4C (NP_002711, 218 a.a. ... protein with GST tag. ... NM_002720 Protein ...
... Eppendorf Thermomixer R offers maximum application ... shaking, heating, and cooling. Its active ... application and temperature control ranges. Five ... 24 micro test tubes, are available ...
Mouse monoclonal antibody raised against a partial recombinant PDE2A. NCBI Entrez Gene ID = PDE2A...
Biology Products: